|
Protocol |
Dose |
Frequency |
Cycle |
|---|---|---|---|
|
Local Growth |
50-100 mcg/muscle |
2-3 times/week (training days) |
4-6 weeks |
|
Systemic |
100 mcg |
1 time/day |
20 days, pause 4 weeks |
|
Regen |
50 mcg |
To target zone |
10-14 days |
After entering the body, DES(1-3) IGF-1 quickly reaches its target through direct interaction with the IGF-1 receptor (IGF-1R). This interaction triggers a cascade of intracellular signaling pathways leading to the following key processes:
Activation of the phosphatidylinositol-3-kinase / protein kinase B / mammalian target of rapamycin (PI3K/Akt/mTOR) pathway: this pathway enhances muscle protein synthesis, promoting muscle hypertrophy and increased muscle strength.
Stimulation of mitogen-activated protein kinases / extracellular signal-regulated kinases (MAPK/ERK): this system stimulates the proliferation of satellite cells, ensuring an increase in the number of new muscle fibers and contributing to tissue hyperplasia.
Additionally, the molecule is capable of interacting with defective forms of receptors (e.g., damaged by lactate), enhancing the effectiveness of action on tissues even under pathological changes. Thus, the effect of DES(1-3) manifests predominantly at the local level, being especially effective when administered via intramuscular injection.
|
Area |
Effects |
|---|---|
|
Muscles |
Local hypertrophy (+20-50%), strength |
|
Regeneration |
Injuries, tendons, cartilage |
|
Fat Burning |
Lipolysis in target zones |
|
Anti-Age |
Collagen↑, skin, bones |
|
Stack |
Effect |
Dose |
|---|---|---|
|
DES IGF + Follistatin |
Myostatin↓ + hyperplasia |
100 mcg + 100 mcg |
|
DES IGF + TB-500 |
Regen x2 |
100 mcg + 2.5 mg |
|
DES IGF + ARA-290 |
Neuroprotection+muscles |
100 mcg + 2 mg |
|
DES IGF + GHRP |
GH synergy |
100 mcg + 100 mcg |
